五度妙笔
API商城
数据库Blueprint Unveiled: The 1st CPIC to Build China’s Answer to the J.P. Morgan Healthcare Conference
The 1st China Pharmaceutical Innovation Conference (CPIC), organized by TONACEA, will be grandly held from July 22 to 24, 2026, at the National Exhibition and Convention Center (Shanghai).
Benchmarking the J.P. Morgan Healthcare Conference, CPIC aims to establish a new paradigm of “China Innovation – Global Translation – Shanghai as a Global Deal-Making Hub.”
This conference is not only a showcase of cutting-edge technologies, but also a strategic platform dedicated to reinforcing the biopharmaceutical sector as a national pillar industry and accelerating the global expansion of China’s innovative drugs.
The event will drive the deep integration of innovation and capital markets, highlight China’s R&D advantage and execution speed, expand global collaboration networks, and significantly enhance the international influence of Chinese innovative therapeutics.
Thousands of global industry leaders will gather in Hongqiao, Shanghai, including representatives from regulatory authorities, multinational pharmaceutical companies, leading research institutions, top biotech firms, international investment banks, professional investors, commercial banks, stock exchanges, and leading law and accounting firms.
Participants will engage in 300+ high-impact sessions and high-frequency 1-on-1 partnering meetings, jointly shaping the future landscape of China’s innovative drugs and medical devices.
As the premier gateway for global capital and enterprises to understand China’s innovation ecosystem, and a core hub for Chinese pharmaceutical companies going global, CPIC is set to become a key barometer for annual investment and collaboration in the global healthcare industry.
The official conference website, registration system, and 1-on-1 partnering platform will be launched soon. Stay tuned.
✓ Biopharmaceuticals as China’s Emerging Pillar Industry
✓ Global Frontiers in Biopharmaceutical Innovation
✓ The Globalization Path of Chinese Pharma
✓ First-in-Class (FIC) and World-Class Drug Development
✓ China’s R&D Advantage and Execution Speed
✓ CPIC Achievement Releases
✓ CPIC Awards Ceremony
✓ CNS Drug Innovation Conference
✓ Cell Therapy & ATMP Conference
✓ In Vivo CAR-T Innovation Forum
✓ Gene Therapy & Rare Disease Drug Development Conference
✓ RNA Therapeutics Conference
✓ mRNA & Vaccine Conference
✓ T-cell Engagers & Next-Generation Antibody Therapeutics
✓ Stem Cell & Regenerative Medicine Technologies
✓ Conjugate Therapeutics Conference
✓ Novel Molecular Entities (NME) Development Conference
✓ Molecular Glues & PROTACs Conference
✓ Organoids & Biochips Conference
✓ Radiopharmaceuticals & Nuclear Medicine Innovation
✓ GLP-1 & Anti-Obesity Drug Development
✓ Biosimilar Development
✓ AI-Driven Drug Discovery Conference
✓ US & EU Regulatory Trends in Drug Approval
✓ China Regulatory Policy No. 818: Translational Pathways for ✓ Biomedical Innovations
✓ China Regulatory Policy No. 828: Accelerating Drug Registration
✓ China–US Drug Registration Compliance
✓ Global Regulatory Frameworks for Medical Devices
✓ IP Strategy in Biopharmaceuticals
✓ Legal Considerations for Global Expansion
✓ Cross-border Transactions & Dispute Resolution
✓ Modular Biopharmaceutical Manufacturing
✓ Digital Factories & Smart Manufacturing
✓ Upstream Supply Chain for Biologics
✓ Bioprocessing & Purification
✓ Cold Chain Logistics Management
✓ Brain-Computer Interface Forum
✓ Academic & Hospital Leadership Forum
✓ Innovative Medical Devices Conference
✓ Biomedical Materials Development
✓ Transformation of Traditional Pharma
✓ Biopharma Industrial Park Ecosystem Development
✓ Tech Transfer & Early-Stage Incubation
✓ Evolution of CRO/CDMO
✓ Leveraging External Partnerships to Accelerate Innovation
✓ From R&D Story to Commercial Success
✓ ESG in Biopharma
✓ IPO Pathways & Regulatory Considerations
✓ Cross-border Financing & USD Fund Strategies
✓ The Rise and Evolution of NewCo Models
✓ Real-World Assets (RWA) as Emerging Financing Tools
✓ Banking & Structured Financing for Biopharma Innovation
✓ M&A in Biopharma
✓ Project Roadshow Sessions
✓ Global BD Strategies and Ecosystem Evolution
✓ Global Branding, Market Access, and Commercial Strategy
✓ Global Commercialization Strategies for Innovative Drugs
✓ Southeast Asia Focus Forum
✓ China–Singapore Collaboration Forum
✓ Hong Kong as a Global Opportunity Hub
✓ China–Europe Collaboration Forum
✓ China–Japan Collaboration Forum
✓ China–Korea Collaboration Forum
✓ Building BD Teams & Global Expansion
✓ Talent Strategy & Organizational Development
✓ Scientist Entrepreneurship Forum
✓ Investor-led Entrepreneurship Forum
✓ 1-on-1 Partnering Meetings
✓ TONACEA Night
✓ Networking Reception
✓ Themed Luncheons
✓ Art & Aesthetic Salon
✓ 10km City Run
✓ Golf Event
✓ Networking Card Games
✓ Biopharma Park Visits
✓ Post-conference Tours for International Guests
And more…
TONACEA is a premier ecosystem platform in China's biopharmaceutical innovation sector. With over 20 years of deep commitment to advancing China's novel drug development, it has evolved into a key organizational force driving the country's pharmaceutical innovation, serving as a core hub connecting multinational pharmaceutical companies with local innovation.
TONACEA brings together multinational pharmaceutical companies, biotech firms, investment institutions, research institutes, and regulatory experts, establishing a high-end professional network and knowledge-sharing ecosystem that spans the entire R&D value chain. Its business scope encompasses industry summits, technical forums, customized corporate training, media communications, and strategic consulting. With branches in Beijing, Shanghai, Suzhou, Guangzhou, Shenzhen, and other cities, TONACEA has built a nationwide operational network.
The TONACEA WeChat official account and video channel consistently deliver in-depth industry insights, with its perspectives frequently cited by investors and media, earning recognition as a trusted "authoritative source" within the industry. The "Huashan Award," co-launched by the platform, sets a benchmark for the globalization of Chinese innovative drugs and empowers local enterprises to step onto the world stage.
Presentation: 20 minutes
Roadshow: 15 minutes
Duration: approximately 40 minutesOpen call for discussion topics and session conveners.
A 10,000 sqm professional exhibition hall will be dedicated to brand showcases and innovation displays.
